LOXL2 and neoplasm: LOXL2 was first found to be downregulated in fibroblasts, head and neck squamous cell carcinoma, lung adenocarcinoma and serous ovarian carcinoma in RAS-transformed mice, and was once considered as a tumor suppressor gene15, 16.